help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarne, D. H.
Right arrow Articles by Farriaux, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarne, D. H.
Right arrow Articles by Farriaux, J. P.

Journal of Clinical Endocrinology & Metabolism, Vol 66, 740-746, Copyright © 1988 by Endocrine Society


ARTICLES

Sex hormone-binding globulin in the diagnosis of peripheral tissue resistance to thyroid hormone: the value of changes after short term triiodothyronine administration

DH Sarne, S Refetoff, RL Rosenfield and JP Farriaux
Department of Medicine, University of Chicago, Illinois 60637.

Thyroid hormone is one of several factors that modulate the level of sex hormone-binding globulin (SHBG) in serum. SHBG levels are usually elevated in thyrotoxicosis and have been reported to be normal in a few patients with generalized resistance to thyroid hormone (GRTH). This study was designed to determine whether basal serum SHBG levels or the SHBG response to short term T3 administration could be used as an index of thyroid hormone action and thus serve as a test for the evaluation of patients suspected of having peripheral tissue resistance to thyroid hormone. Serum SHBG, total T4, free T4 index (FT4I), total T3, and TSH levels were measured in 21 normal subjects, 28 hypothyroid patients, 20 thyrotoxic patients, and 10 patients with GRTH. Excluding patients with GRTH, serum basal SHBG values were correlated with FT4I values (r = 0.66; P less than 0.0001). Mean SHBG levels in the patients with GRTH [37.6 +/- 16.2 (+/- SD) nmol/L] were not significantly different from those in the normal subjects (35.1 +/- 19.3 nmol/L) or hypothyroid patients (26.3 +/- 17.1 nmol/L), but were significantly lower than those in the thyrotoxic group (64.7 +/- 19.2 nmol/L; P less than 0.001). All 10 patients with GRTH had basal SHBG values in the normal range, but 7 of 20 (35%) thyrotoxic patients also had normal basal SHBG values. T3 was given orally for three sequential 3-day periods at doses of 50, 100, and 200 micrograms daily to 7 normal subjects, 11 hypothyroid and 3 thyrotoxic patients, and all 10 patients with GRTH. The serum SHBG concentration was measured on the last day at each dosage level. During T3 administration, SHBG levels increased in all individuals with normal tissue responsiveness. The increase above the basal value (delta SHBG) at each T3 dose was similar in normal, hypothyroid, and thyrotoxic individuals (non-resistant subjects). After administration of 50 micrograms T3 daily, the mean delta SHBG level was decreased [-2.9 +/- 5.3 (+/- SD) nmol/L] in the resistant patients and increased (4.0 +/- 4.9 nmol/L; P less than 0.005) in the nonresistant subjects. After administration of 100 micrograms T3 daily, the mean delta SHBG was -4.5 +/- 6.8 nmol/L in the resistant patients and 8.6 +/- 5.1 nmol/L (P less than 0.0001) in the nonresistant subjects. Serum SHBG decreased by more than 2 nmol/L in 6 of 10 (60%) resistant patients, but in no nonresistant subject.(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
C. Carani, A. M. Isidori, A. Granata, E. Carosa, M. Maggi, A. Lenzi, and E. A. Jannini
Multicenter Study on the Prevalence of Sexual Symptoms in Male Hypo- and Hyperthyroid Patients
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6472 - 6479.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
S. S. Girdler, K. S. Thompson, K. C. Light, J. Leserman, C. A. Pedersen, and A. J. Prange Jr.
Historical Sexual Abuse and Current Thyroid Axis Profiles in Women With Premenstrual Dysphoric Disorder
Psychosom Med, May 1, 2004; 66(3): 403 - 410.
[Abstract] [Full Text] [PDF]


Home page
Alcohol AlcoholHome page
H. Iturriaga, X. Lioi, and L. Valladares
SEX HORMONE-BINDING GLOBULIN IN NON-CIRRHOTIC ALCOHOLIC PATIENTS DURING EARLY WITHDRAWAL AND AFTER LONGER ABSTINENCE
Alcohol Alcohol., November 1, 1999; 34(6): 903 - 909.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. Bunevicius, G. Kazanavicius, R. Zalinkevicius, and A. J. Prange
Effects of Thyroxine as Compared with Thyroxine plus Triiodothyronine in Patients with Hypothyroidism
N. Engl. J. Med., February 11, 1999; 340(6): 424 - 429.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Janne and G. L. Hammond
Hepatocyte Nuclear Factor-4 Controls Transcription from a TATA-less Human Sex Hormone-binding Globulin Gene Promoter
J. Biol. Chem., December 18, 1998; 273(51): 34105 - 34114.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society